



According to the original version from the Register of Minutes of Management Board meetings

Extract no. 1 of the Minutes no.3 dated 15.03.2017 concluded in the meeting of the Management Board of Antibiotice SA lasi

The Managing Board of Antibiotice decides the approval of the following materials on the agenda of the GMS meeting held on 06/07.04.2017:

- 1. Approval of the company's financial statement for the fiscal year 2016, based on the Management Report and Financial Auditor Report.
- 2. Approval of net profit distribution on 2016, setting the gross dividend per share and setting the payment date on 15.09.2017.
- 3. Approval for registering the unsolicited and unclaimed dividends for the financial year 2012 as revenues.
- 4. Approving the discharge of administration for the activity conducted in the fiscal year 2016, based on reports submitted.
- 5. Approving the income and expenditure budget on 2017.
- 6. Approval of the degree of achieving the objectives and performance criteria on 2016 for the members of the Management Board.
- 7. Approving the objectives set in the administration plan for the members of the Management Board for 2017.
- 8. Setting the remuneration for the members of the Management Board as per GEO no. 109/2011 (L111/2016) on corporate governance of public enterprises.
- 9. Approving the registration date **01.09.2017** in order to identify the shareholders subject to the effects of the decisions adopted, as per the stipulations of art. 238 paragraph 1 of Law 297/2004 regarding the capital market, amended by provisions L10/2015 and setting the exdate **31.08.2017**.
- 10. Approval to extend by 12 months the validity period of the multicurrency multiproduct credit amounting to 30 million RON borrowed by Antibiotice from the Export Import Bank of Romania- Eximbank.
- 11. Approval to maintain the guarantees relative to the multicurrency multiproduct amounting to 30 million RON throughout the entire term of validity resulting from 1 on the Agenda.

- 12. Issuing a decision-commitment of Antibiotice not to divide itself, not to merge and decide the anticipated dissolution throughout the entire validity period of the multicurrency multiproduct without prior consent of Eximbank SA.
- 13. Empowering the General Manager Mr. Ioan NANI and Financial Director Ms. Paula COMAN to sign on behalf of the company all documents related to the credit facility extension and changes, under paragraphs 1 and 2 of the agenda, as well as documents related to obligations assumed by the company in accordance with paragraphs 3 of the agenda
- 14. Modifying and updating the following articles of the Articles of Association
- 15. Setting the company's representative office in Vietnam, in the building Sannam str. Duy Tan 78, Dich Vong Hau Ward, sector Cau Giay, Hanoi.
- 16. Approval of the date of **01.09.2017** as the registration date for identifying the shareholders who are affected by the decisions adopted, according to the provisions of the art. 238, para. 1 of Law 297/2004 on the capital market, amended and supplemented by the provisions of Law 10/2015 and the establishment of the ex-date for 31.08.2017.

Vicepresident of Management Board and Director General of Antibiotice Economist Ioan NANI

> Secretary of the GMS, Economist Dana SACARESCU